ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bosentan

Also written as “bosentan”, “Bosentan 125 mg” and “Bosentan 62.5 mg”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Idiopathic Pulmonary Fibrosis · digital ulcers · Scleroderma, Systemic, led by 5 companies.

Drug pageBosentan: every studyMany companies study it; this page follows only the 30 they lead. All 85 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 30, 200430 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only260 open or runningphase 4since Apr 30, 2004Oct 6, 2003none ahead
Geropharmits history only10 open or runningphase 1since Sep 23, 2019Sep 23, 2019none ahead
Hanmi Pharmaceuticalits history only10 open or runningphase 1since May 20, 2013May 20, 2013none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jun 26, 2024Jun 26, 2024none ahead
Retinset SL10 open or runningphase 1since Aug 22, 2019Aug 22, 2019none ahead

Also a collaborator on its studies: Dong-A ST.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Retinset SL only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 22, 2019First study: phase 1 study in Diabetes MellitusFirst studyNCT04068272 · 22 enrolled · Spain

TargetBeta

EDNRA →EDNRB →read by rule
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
aprocitentanruleIdorsia Pharmaceuticalsphase 314

Studies

The one study Retinset SL leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04068272Diabetes Mellitus · Spain1CompletedMay 20, 202222

How it is read

Names in the registry

  • “Bosentan”, 19 entries
  • “bosentan”, 12 entries
  • “Bosentan 125 mg”, 3 entries
  • “Bosentan 62.5 mg”, 2 entries
  • “Bosentan Dispersible Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.